ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1062

Impact of Obesity on 1 Year Outcomes: Results from the Meteor Foundation International Rheumatoid Arthritis Cohort

Christopher Sparks1, Robert Moots1, Eftychia Psarelli2, Tom Huizinga3 and Nicola Goodson1, 1Musculoskeletal Biology1, University of Liverpool, Liverpool, United Kingdom, 2Cancer Research UK Liverpool Cancer Trials Unit, University of Liverpool, Liverpool, United Kingdom, 3Rheumatology, Leiden University Medical Center, Leiden, Netherlands

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: body mass, Disease Activity, longitudinal studies, obesity and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Public Health (ACR): Rheumatoid Arthritis and Systemic Lupus Erythematosus Outcomes

Session Type: Abstract Submissions (ACR)

Background/Purpose

Increased adiposity is associated with increased production of pro-inflammatory adipokines and raised inflammatory markers. As a result, standard disease activity scores (DAS) may be greater in obese rheumatoid arthritis (RA) patients, with important implications for their treatment in modern target based regimens. There is limited longitudinal evidence assessing the impact of obesity on DAS. We sought to investigate the influence of obesity on 1 year outcomes in a large international RA cohort.

Methods

Patients with a clinical diagnosis of RA with complete 6 and 12 month follow up from the METEOR Foundation International RA database were identified. The cohort was divided into early RA (eRA, disease duration <12 months) and established RA subgroups (disease duration ≥12 months). Patient demographics, DAS28, Health Assessment Questionnaire (HAQ) score and BMI were collected from the first recorded visit on the database. The cohorts were stratified into 4 categories by BMI: 1) Underweight <18.5, 2) Normal 18.5-24.9, 3) Overweight 25-29.9 and 4) Obese ≥30. Outcomes of interest were: good EULAR response (DAS28), low disease activity (DAS28 <3.2) and DAS28 remission (DAS28 <2.6) at follow up. Associations between BMI category and outcome measures at follow up (6 and 12 months) were explored using multivariate logistic regression analysis for both the eRA and established RA cohorts, adjusting for age, gender and smoking status.

Results

1,525 patients with complete data were identified. Mean age was 53.2 (SD 13.2) and 78.8% were female. The eRA and established RA subgroups contained 641 and 884 patients respectively, with a similar distribution of BMI categories seen in both groups (mean BMI 26.8 (SD 5.6) and 26.8 (SD 5.07) respectively).

At baseline median DAS28 scores for each BMI category were similar to those described for this cohort previously.1Logistic regression analysis found no associations between overweight or obese BMI categories and clinical outcomes at 6 or 12 month follow up in the eRA subgroup. However, underweight patients had a lower probability of achieving low disease activity at 6 and 12 months (OR 0.24 (95%CI 0.07, 0.85) and OR 0.14 (95%CI 0.03, 0.62) respectively).

Analysis of the established RA subgroup identified obese patients to be significantly less likely to exhibit low disease activity at 6 and 12 month follow up, or disease remission at 12 months follow up (Table 1).

Table 1. Multivariate adjusted offs ratio (95% Confidence Intervals) for association between disease activity and BMI category for the established RA cohort.

Variable

Underweight

(n=12)

Normal (r) (n=359)

Overweight

(n=313)

Obese

(n=200)

Good Response 6 months

0.42 (0.05, 3.37)

1.0

0.90 (0.60, 1.35)

0.59 (0.36, 0.97)

DAS28 <3.2 at 6 months

1.23 (0.38, 3.99)

1.0

0.83 (0.60, 1.13)

0.55 (0.39, 0.80)

DAS28 <2.6 at 6 months

0.62 (0.16, 2.38)

1.0

0.84 (0.60, 1.16)

0.48 (0.32, 0.72)

Good Response 12 months

0.39 (0.05, 3.15)

1.0

0.80 (0.54, 1.20)

0.97 (0.63, 1.52)

DAS28 <3.2 at 12 months

1.89 (0.55, 6.48)

1.0

1.12 (0.82, 1.53)

0.77 (0.54, 1.10)

DAS28 <2.6 at 12 months

0.97 (0.28, 3.38)

1.0

0.86 (0.62, 1.20)

0.62 (0.42, 0.92)

Conclusion

Obese patients with RA appear to respond to treatment, and achieve treatment goals within the first year following diagnosis. Outside of this period, obese patients are less likely to reach low disease activity or disease remission. These findings may have important implications for treatment objectives in modern target based regimens.

References

1Sparks CR, Moots RJ, Goodson NJ. OBESITY AND DISEASE ACTIVITY IN A LARGE INTERNATIONAL RHEUMATOID ARTHRITIS COHORT. Ann Rheum Dis 2014;73(Suppl 2):136-137


Disclosure:

C. Sparks,
None;

R. Moots,
None;

E. Psarelli,
None;

T. Huizinga,
None;

N. Goodson,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-obesity-on-1-year-outcomes-results-from-the-meteor-foundation-international-rheumatoid-arthritis-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology